English
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Efficacy and Safety of Different Doses of Vaginal Misoprostol Prior to Intra Uterine Contraceptive Device Insertion

Only registered users can translate articles
Log In/Sign up
The link is saved to the clipboard
StatusCompleted
Sponsors
Ain Shams University

Keywords

Abstract

investigators aim through this study to evaluate and compare the Safety and efficacy of different doses of misoprostol prior to IUCD insertion among women with nulliparous cervix beside the rate of occurrence of adverse effects.

Description

Today there is an ever-increasing variety of effective contraceptive methods. Although all have side effects, they offer a lower risk than that conferred by pregnancy Contraceptive methods are classified according to their effectiveness. The top tier offer the highest level of effectiveness (defined as

Although intrauterine devices (IUDs) are safe, reliable and highly effective forms of long- acting reversible contraception and has a very low failure rate (0.2-0.6 per 100 women per year) , it is used by only 7.6% and 14.5% of contraceptive users in developed and developing countries, respectively

According to the latest practice recommendations for contraceptive use by the Centers for Disease Control and Prevention, the potential barriers to IUD use include anticipated insertion pain and health care providers' concerns about difficult insertion ( It is therefore important to identify effective approaches to ease IUD insertion in order to overcome obstacles hindering IUD use

Insertion-associated pain is related to speculum insertion, tenaculum traction on the cervix, sounding of the uterus, passing of the insertion tube through the cervix and placement of the device within the uterine cavity

Failure of insertion occurs in up to 14% and 20% of parous and nulliparous women, respectively 13).

It has been suggested that difficulty and failure of insertion are experienced more in nulliparous women (adjusted odds ratio [AOR] 5.19; 95% confidence interval [CI] 2.49, 10.82) and in those with previous Caesarean delivery (AOR 5.38; 95% CI 2.58, 11.22), due to a narrower cervical os Fouda et al. found that women who had delivered only by Caesarean section experienced more pain with IUD insertion compared with women with previous vaginal delivery

Many investigators have studied how to minimize insertion pain or failure. Few studies, however, have assessed any measure to decrease pain or difficulty during IUD insertion in women with previous Caesarean delivery (and no prior vaginal delivery) Pergialiotis et al. conducted a meta-analysis of clinical trials of analgesic options for IUD placement. Owing to the small number of trials, however, they concluded that further studies were needed before a conclusion could be reached

Misoprostol is a synthetic analog of prostaglandin E1 originally approved for treatment and prevention of gastric ulcers induced by non steroidal anti inflammatory drugs. It can be administered sublingually, orally, vaginally, or rectally. Vaginal administration has been associated with the highest peak serum levels of misoprostol, and overall bioavailability is greatest for sublingual and vaginal administration.

Misoprostol has well-known cervical ripening and uterotonic effects, naturally leading to its use as an adjunct in many gynecologic procedures. Its use has been well studied in the hysteroscopy literature. Multiple well-designed studies have validated the efficacy of different doses of misoprostol before hysteroscopy in reducing pain with dilation, reducing the number of failed dilations, and increasing cervical canal diameter before dilation Given these data, it is reasonable to hypothesize that pretreatment with misoprostol could aid in IUD insertion.

As existing studies examining this question have asserted varied conclusions, through this study investigators will evaluate and compare the safety and efficacy of different doses of misoprostol prior to IUCD insertion among women with nulliparous cervix beside the rate of occurrence of adverse effects.

This study aims to compare the efficacy and safety of different doses of vaginal misoprostol prior to IUCD insertion among women with nulliparous cervix "those who never delivered vaginally".

Dates

Last Verified: 06/30/2020
First Submitted: 02/09/2020
Estimated Enrollment Submitted: 02/16/2020
First Posted: 02/17/2020
Last Update Submitted: 07/12/2020
Last Update Posted: 07/13/2020
Actual Study Start Date: 02/29/2020
Estimated Primary Completion Date: 06/14/2020
Estimated Study Completion Date: 06/29/2020

Condition or disease

Intra-uterine Device Complication

Intervention/treatment

Drug: Misoprostol

Phase

Phase 4

Arm Groups

ArmIntervention/treatment
Active Comparator: 1- Group 1 (misoprostol 200 mcg
Group 1 :will take 1 tablet (200 mcg) of misoprostol and 1 placebo tablet, .,
Active Comparator: 2- Group 2 (misoprostol 100 mcg)
Group 2: will take1 tablet (100 mcg) of misoprostol and 1 placebo tablet,
Placebo Comparator: 3- Group 3 (placebo group)
Group 3 ): will take2 placebo tablets

Eligibility Criteria

Ages Eligible for Study 18 Years To 18 Years
Sexes Eligible for StudyFemale
Accepts Healthy VolunteersYes
Criteria

Inclusion Criteria:

- Non-pregnant,

- Nulliparous cervix: no previous vaginal delivery or any attempt of vaginal delivery,

- Seeking for IUD insertion,

- Signing an informed consent to participate in the study,

Exclusion Criteria:

- Pregnancy or signs of pregnancy,

- Signs of cervicitis,

- Any uterine abnormalities as congenital anomalies, endometrial lesions, adenomyosis, fibroids and intrauterine adhesions,

- Women with any kind of pelvic pain,

- Abnormal uterine bleeding,

- History of cervical surgery,• Vaginal delivery,

- Contraindication to misoprostol as allergy,

- Administration of any analgesics last 12h,

- Withdrawal of consent

Outcome

Primary Outcome Measures

1. Pain scores [during insertion of IUCD]

Pain scores will be measured using a visual analogue scale (VAS) consisting of a 10 cm horizontal straight line on which 0 cm corresponded to no pain and 10 cm to the worst pain. The pain score will be measured within 5 min of insertion of the IUD tube.

Secondary Outcome Measures

1. The ease of IUD insertion [during insertion ofIUCD]

The ease of IUD insertion: using the ease of insertion score (ES): a graduated VAS-like scale from 0 to 10; in which 10 means terribly difficult insertion and 0 means very easy insertion. The ES was validated for use in previous similar studies about IUD insertion (Abbas et al., 2017).

2. Successful IUD insertion [5minutes after insertion of IUCD]

Successful IUD insertion which will be assessed by vaginal US device 'Samsung h 60' through the following criteria: IUD is centrally located within the endometrial cavity The crossbar is positioned in the fundal area. The distance from the top of the uterine cavity to the IUD should be 3 mm or less. This ultrasound scan will be performed just after the IUCD insertion.

3. The duration of insertion in seconds [during insertion ofIUCD]

The duration of insertion in seconds: starting from putting loaded applicator at the external os till withdrawal of the applicator after IUD insertion

4. The women's level of satisfaction at the end of insertion [1 miute after insertion of IUCD]

The women's level of satisfaction at the end of insertion: every woman will express her level of satisfaction with IUD insertion by completing a 10-cm VAS (with 0 = no satisfaction and 10 = maximum satisfaction).

Other Outcome Measures

1. The side effects of the study medication [within 3 hours from inserting the misoprostol tablet]

as shivering, nausea, vomiting and diarrhea

2. Complications from IUD insertion [during insertion ofIUCD]

as abdominal cramps, uterine bleeding, perforation and cervical trauma

3. The number of women who need additional analgesics after the insertion [5 minutes after insertion]

4. Failure of IUD insertion, due to technical difficulty or intolerance of the patient [during IUCD insertion]

Join our facebook page

The most complete medicinal herbs database backed by science

  • Works in 55 languages
  • Herbal cures backed by science
  • Herbs recognition by image
  • Interactive GPS map - tag herbs on location (coming soon)
  • Read scientific publications related to your search
  • Search medicinal herbs by their effects
  • Organize your interests and stay up do date with the news research, clinical trials and patents

Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against.
*All information is based on published scientific research

Google Play badgeApp Store badge